Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

SH Lim; HS Sow; C Wignall; K Mercer; J Caddy; C Boxall; K Thorne; J Northey; L Stanton; Z Konn; K Fines; PG Medd; A Coleman; L Nunn; R Lown; P Mckay; W Osborne; K Linton; GP Collins; AJ Gentles; M Rose-Zerilli; G Griffiths

doi:10.1182/blood-2021-148332

Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

SH Lim
, HS Sow
, C Wignall
, K Mercer
, J Caddy
, C Boxall
, K Thorne
, J Northey
, L Stanton
, Z Konn
, K Fines
, PG Medd
, A Coleman
, L Nunn
, R Lown
, P Mckay
, W Osborne
, K Linton
, GP Collins
, AJ Gentles

M Rose-Zerilli, G Griffiths

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	5
Journal	Blood
Volume	138
DOIs	https://doi.org/10.1182/blood-2021-148332
Publication status	Published - 23 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2021-148332

Cite this

Lim, SH., Sow, HS., Wignall, C., Mercer, K., Caddy, J., Boxall, C., Thorne, K., Northey, J., Stanton, L., Konn, Z., Fines, K., Medd, PG., Coleman, A., Nunn, L., Lown, R., Mckay, P., Osborne, W., Linton, K., Collins, GP., ... Griffiths, G. (2021). Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial. Blood, 138. https://doi.org/10.1182/blood-2021-148332

@article{543f0624c03d424cb01cb8f2b52f59bc,

title = "Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial",

author = "SH Lim and HS Sow and C Wignall and K Mercer and J Caddy and C Boxall and K Thorne and J Northey and L Stanton and Z Konn and K Fines and PG Medd and A Coleman and L Nunn and R Lown and P Mckay and W Osborne and K Linton and GP Collins and AJ Gentles and M Rose-Zerilli and G Griffiths",

year = "2021",

month = nov,

day = "23",

doi = "10.1182/blood-2021-148332",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}

Lim, SH, Sow, HS, Wignall, C, Mercer, K, Caddy, J, Boxall, C, Thorne, K, Northey, J, Stanton, L, Konn, Z, Fines, K, Medd, PG, Coleman, A, Nunn, L, Lown, R, Mckay, P, Osborne, W, Linton, K, Collins, GP, Gentles, AJ, Rose-Zerilli, M & Griffiths, G 2021, 'Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial', Blood, vol. 138. https://doi.org/10.1182/blood-2021-148332

TY - JOUR

T1 - Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma

T2 - The Riva Trial

AU - Lim, SH

AU - Sow, HS

AU - Wignall, C

AU - Mercer, K

AU - Caddy, J

AU - Boxall, C

AU - Thorne, K

AU - Northey, J

AU - Stanton, L

AU - Konn, Z

AU - Fines, K

AU - Medd, PG

AU - Coleman, A

AU - Nunn, L

AU - Lown, R

AU - Mckay, P

AU - Osborne, W

AU - Linton, K

AU - Collins, GP

AU - Gentles, AJ

AU - Rose-Zerilli, M

AU - Griffiths, G

PY - 2021/11/23

Y1 - 2021/11/23

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000736398803015&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1182/blood-2021-148332

DO - 10.1182/blood-2021-148332

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

ER -

Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

UN SDGs

Access to Document

Other files and links

Cite this